Alkermes Starts Phase 3 Program for Narcolepsy Drug Candidate Alixorexton
It will analyze once-daily and split-dose regimens of the oral orexin 2 receptor agonist in people with narcolepsy type 1 and type 2.
Tag: narcolepsy type 2
All
Latest
All
Latest
Takeda to Unveil Latest TAK-861 Data in Narcolepsy at Sleep Europe 2024
Takeda will present additional data from phase 2b and long-term extension trials of its investigational orexin receptor 2 agonist, TAK-861.
All
Latest
Is It Idiopathic Hypersomnia or Narcolepsy? Brain Imaging May Hold Answers
Brain imaging research identifies differences in brain structure and activity that could help in understanding and distinguishing IH.
Alkermes Reports First Profitable Quarter, Advances Narcolepsy Drug Studies
The company highlights progress in developing a novel narcolepsy treatment, with a new phase 2 study underway.
Read More
Alkermes’ Orexin-2 Receptor Agonist for Narcolepsy Enters Phase 2 Trials
The phase 2 trial will evaluate the safety and efficacy of ALKS 2680, a novel orexin-2 receptor agonist, in patients with narcolepsy type 1.
Read More
FDA Greenlights Phase 1 Trial of Narcolepsy Drug Candidate ORX750
The clinical trial will evaluate the safety, tolerability, and pharmacokinetics of Centessa Pharmaceuticals’ orexin receptor 2 agonist.
Read More
Investigational Orexin-2 Receptor Agonist Improves Wakefulness in Narcolepsy Type 2 and IH
Alkermes plc announced positive results from a phase 1b study evaluating ALKS 2680 for treating narcolepsy type 2 and idiopathic hypersomnia.
Read More
Takeda’s Oral Orexin Agonist to Enter Phase 3 Trials in Narcolepsy Type 1
Takeda announced positive results from a phase 2b trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.
Read More
Physician Discovers Surprising Possible Side Effect of Xywav in Narcolepsy Patient
A patient with type 2 narcolepsy reports an experience to her sleep physician that was not seen in any of the clinical trials.
Read More
Patient-Led Initiative to Propel Development of Sleep Disorder Treatments
The program will provide researchers with the opportunity to request and analyze high-quality data and enable individuals with primary central disorders of hypersomnolence to share their data.
Read More
Zevra to Begin Clinical Trial of KP1077 in Narcolepsy
The phase 1 clinical trial is expected to provide additional information regarding the optimal dosing regimen.
Read More
New Pediatric Hypersomnolence Survey Screens for Symptom Onset in Children
The Pediatric Hypersomnolence Survey is designed to improve early identification of narcolepsy (type 1 and type 2) and idiopathic hypersomnia among children and adolescents.
Read More